MetaCap

Bristol-Myers Squibb (BMY) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bristol-Myers Squibb (BMY) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 27.1% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +4.0% for BMY. Vertex Pharmaceuticals is the larger company by market cap ($130.58 billion vs $120.19 billion), about 1.1 times the size.

On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.8x vs 25.9x for Vertex Pharmaceuticals). Bristol-Myers Squibb pays a dividend yielding 4.29%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 14.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMY+27.14%VRTX+20.68%
+50%+23%-3%
Nov 21, 20251 yearNov 20, 2026
BMY+1.68%VRTX+181.62%
+217%+87%-43%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMY versus VRTX key metrics
MetricBMYVRTX
Share price$58.80$515.02
Market cap$120.19B$130.58B
1-day change+0.79%-1.08%
YTD return+9.01%+13.60%
1-year return+27.14%+20.68%
5-year return+4.02%+180.53%
P/E ratio (TTM)13.0433.14
Forward P/E8.7825.86
EPS (TTM)$4.51$15.54
Dividend yield4.29%0.00%
Annual dividend$2.52$0.00
Revenue (latest FY)$48.19B$12.00B
Revenue growth (YoY)-0.22%+8.90%
Net income (latest FY)$7.05B$3.95B
Gross margin71.08%86.24%
Operating margin—34.77%
Net margin14.64%32.94%
52-week high$68.64$568.67
52-week low$47.58$412.27
Distance from 52-week high-14.34%-9.43%
Analyst consensusbuybuy
Avg. price target upside+10.97%+15.60%
Average volume11.15M1.25M
Shares outstanding2.04B253.54M
Employees32,5006,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vertex Pharmaceuticals trades at a higher earnings multiple (33.1x vs 13.0x trailing P/E).
  • Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.29% vs 0.00%).
  • Vertex Pharmaceuticals is more profitable, keeping 32.9 cents of every revenue dollar as net income versus 14.6 cents for Bristol-Myers Squibb.
  • Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs -0.22%).

About Bristol-Myers Squibb

BMY stock →

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

BMY vs VRTX FAQ

Which is bigger, Bristol-Myers Squibb or Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $130.58B compared with $120.19B for Bristol-Myers Squibb (BMY).

Which stock has performed better over the past year, BMY or VRTX?

BMY returned +27.14% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BMY or VRTX?

BMY has the lower trailing P/E at 13.0, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Bristol-Myers Squibb or Vertex Pharmaceuticals?

Bristol-Myers Squibb pays a dividend yielding 4.29%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Bristol-Myers Squibb and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons